Photo of S. J. Adelstein,  MD, PhD

S. J. Adelstein, MD, PhD

Harvard Medical School

Harvard Medical School
Phone: (617) 432-3997
Fax: (617) 432-0173


james_adelstein@hms.harvard.edu

S. J. Adelstein, MD, PhD

Harvard Medical School

EDUCATIONAL TITLES

  • Paul C. Cabot Distinguished Professor of Medical Biophysics, Radiology, Harvard Medical School
  • Professor, Nuclear Medicine, Harvard Medical School
  • Senior Radiologist, Nuclear Medicine, Brigham And Women's Hospital

Research Abstract

Our laboratory studies the biophysical effects of densely ionizing radiation and its application to experimental cancer therapy. The interaction of alpha particles as well as Auger and Koster-Cronig electrons wtih chromosal DNA and its consituents is a central focus. Biological endpoints include double strand breaks, clonal survival, transformation and mutagenesis. The information obtained from these studies is used in the development of agents for targeted radionuclide therapy.We are also interested in cell surface enzymes and mitochondrial membranes as targets for radio-labeled imaging and therapeutic probes.

Publications

Powered by Harvard Catalyst
  • Adelstein SJ. Radiation Risk in Nuclear Medicine. Semin Nucl Med 2014; 44:187-192. PubMed
  • Mamlouk O, Balagurumoorthy P, Wang K, Adelstein SJ, Kassis AI. Bystander effect in tumor cells produced by Iodine-125 labeled human lymphocytes. Int J Radiat Biol 2012. PubMed
  • Yang Y, Adelstein SJ, Kassis AI. General approach to identifying potential targets for cancer imaging by integrated bioinformatics analysis of publicly available genomic profiles. Mol Imaging 2011; 10:123-34. PubMed
  • Hricak H, Brenner DJ, Adelstein SJ, Frush DP, Hall EJ, Howell RW, McCollough CH, Mettler FA, Pearce MS, Suleiman OH, Thrall JH, Wagner LK. Managing radiation use in medical imaging: a multifaceted challenge. Radiology 2011; 258:889-905. PubMed
  • Yang Y, Adelstein SJ, Kassis AI. Integrated bioinformatics analysis for cancer target identification. Methods Mol Biol 2011; 719:527-45. PubMed
  • Yang S Y, Adelstein J, Kassis AI. Putative molecular signatures for the imaging of prostate cancer. Expert Rev Mol Diagn 2009; 10:65-74. PubMed
  • Howell RW,Martin RF,Nikjoo H,Pomplun E,Terrissol M,Watanable R,Yasui L,Kassis AI,Adelstein SJ. Meeting overview. Int J Radiat Biol 2008; 84:957-8. PubMed
  • Singh A,Yang Y,Adelstein SJ,Kassis AI. Synthesis and application of molecular probe for detection of hydroxyl radicals produced by Na(125)I and gamma-rays in aqueous solution. Int J Radiat Biol 2008; 84:1001-10. PubMed
  • Balagurumoorthy P,Wang K,Adelstein SJ,Kassis AI. DNA double-strand breaks induced by decay of (123)I-labeled Hoechst 33342: role of DNA topology. Int J Radiat Biol 2008; 84:976-83. PubMed
  • Balagurumoorthy P,Adelstein SJ,Kassis AI. Method to eliminate linear DNA from mixture containing nicked circular, supercoiled, and linear plasmid DNA. Anal Biochem 2008; 381:172-4. PubMed
  • Balagurumoorthy P,Chen K,Adelstein SJ,Kassis AI. Auger electron-induced double-strand breaks depend on DNA topology. Radiat Res 2008; 170:70-82. PubMed
  • Wang K, Adelstein SJ, Kassis AI. DMSO increases radioiodination yield of radiopharmaceuticals. Appl Radiat Isot 2007; 66:50-9. PubMed
  • Kassis AI, Korideck H, Wang K, Pospisil P, Adelstein SJ. Novel prodrugs for targeting diagnostic and therapeutic radionuclides to solid tumors. Molecules 2008; 13:391-404. PubMed
  • Wong RC, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA, Empson M, Gillis D, Hendle MJ, Laurent R, Mallon D, Pollock W, Smith S, Steele RH, Wilson RJ. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology 2007; 40:58-63. PubMed
  • Wang K, Kirichian AM, Aowad AF, Adelstein SJ, Kassis AI. Evaluation of chemical, physical, and biologic properties of tumor-targeting radioiodinated quinazolinone derivative. Bioconjug Chem 2007; 18:754-64. PubMed
  • Pospisil P, Wang K, Al Aowad AF, Iyer LK, Adelstein SJ, Kassis AI. Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors. Cancer Res 2007; 67:2197-205. PubMed
  • Chen K, Aowad AF, Adelstein SJ, Kassis AI. Molecular-docking-guided design, synthesis, and biologic evaluation of radioiodinated quinazolinone prodrugs. J Med Chem 2007; 50:663-73. PubMed
  • Chen K, Wang K, Kirichian AM, Al Aowad AF, Iyer LK, Adelstein SJ, Kassis AI. In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy. Mol Cancer Ther 2006; 5:3001-13. PubMed
  • Urashima T, Nagasawa H, Wang K, Adelstein SJ, Little JB, Kassis AI. Induction of apoptosis in human tumor cells after exposure to Auger electrons: comparison with gamma-ray exposure. Nucl Med Biol 2006; 33:1055-63. PubMed
  • Balagurumoorthy P, Chen K, Bash RC, Adelstein SJ, Kassis AI. Mechanisms underlying production of double-strand breaks in plasmid DNA after decay of 125I-Hoechst. Radiat Res 2006; 166:333-44. PubMed
  • Pospisil P, Iyer LK, Adelstein SJ, Kassis AI. A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics 2006; 7:354. PubMed
  • Kishikawa H, Wang K, Adelstein SJ, Kassis AI. Inhibitory and stimulatory bystander effects are differentially induced by Iodine-125 and Iodine-123. Radiat Res 2006; 165:688-94. PubMed
  • Semnani ES, Wang K, Adelstein SJ, Kassis AI. 5-[123I/125I]iodo-2'-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting. J Nucl Med 2005; 46:800-6. PubMed
  • Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005; 46 Suppl 1:4S-12S. PubMed
  • Urashima T, Wang K, Adelstein SJ, Kassis AI. Activation of diverse pathways to apoptosis by (125)IdUrd and gamma-photon exposure. Int J Radiat Biol 2005; 80:867-74. PubMed
  • Kassis AI, Kirichian AM, Wang K, Semnani ES, Adelstein SJ. Therapeutic potential of 5-[125I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol 2005; 80:941-6. PubMed
  • Chen K, Adelstein SJ, Kassis AI. Molecular simulation of ligand-binding with DNA: implications for 125I-labeled pharmaceutical design. Int J Radiat Biol 2005; 80:921-6. PubMed
  • Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med 2003; 44:1945-61. PubMed
  • Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: background to therapy. Cancer Biother Radiopharm 2003; 18:301-16. PubMed
  • Adelstein SJ. Biologic responses to low doses of ionizing radiation: adaptive response versus bystander effect. J Nucl Med 2003; 44:125; author reply 125-6. PubMed
  • Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002; 99:13765-70. PubMed
  • Ho NH, Harapanhalli RS, Dahman BA, Chen K, Wang K, Adelstein SJ, Kassis AI. Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconjug Chem 2002; 13:357-64. PubMed
  • Adelstein SJ. Robley Evans and what physics can do for medicine. Cancer Biother Radiopharm 2001; 16:179-85. PubMed
  • Walicka MA, Adelstein SJ, Kassis AI. Chemical modification of 5-[125I]iodo-2'-deoxyuridine toxicity in mammalian cells in vitro. Int J Radiat Biol 2001; 77:625-30. PubMed
  • Adelstein SJ. The 2000 NCRP Lauriston S. Taylor lecture--administered radioactivity: unde venimus quoque imus. National Council on Radiation Protection and Measurements. Health Phys 2001; 80:317-24. PubMed
  • Walicka MA, Ding Y, Adelstein SJ, Kassis AI. Morphological transformation of C3H 10T1/2 cells by 99mTc-cardiolite. J Nucl Med 2000; 41:1545-51. PubMed
  • Walicka MA, Ding Y, Adelstein SJ, Kassiss AI. Toxicity of DNA-incorporated iodine-125: quantifying the direct and indirect effects. Radiat Res 2000; 154:326-30. PubMed
  • Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med 1998; 39:1148-54. PubMed
  • Walicka MA, Adelstein SJ, Kassis AI. Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: double-strand breaks. Radiat Res 1998; 149:134-41. PubMed
  • Walicka MA, Adelstein SJ, Kassis AI. Indirect mechanisms contribute to biological effects produced by decay of DNA-incorporated iodine-125 in mammalian cells in vitro: clonogenic survival. Radiat Res 1998; 149:142-6. PubMed
  • Sahu SK, Wen PY, Foulon CF, Nagel JS, Black PM, Adelstein SJ, Kassis AI. Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases. J Nucl Med 1997; 38:386-90. PubMed
  • Kassis AI, Adelstein SJ, Mariani G. Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Q J Nucl Med 1996; 40:301-19. PubMed
  • Mariani G, Di Sacco S, Volterrani D, Di Luca L, Buralli S, Di Stefano R, Baranowska-Kortylewicz J, Bonora D, Matteucci F, Ricci S, Bellina CR, Falcone A, Salvadori PA, Mosca F, Adelstein SJ, Kassis AI. Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 1996; 37:22S-25S. PubMed
  • Mariani G, Collecchi P, Baldassarri S, Di Luca L, Buralli S, Fontanini G, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI. Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2'- deoxyuridine after intravesical infusion in patients with bladder cancer. J Nucl Med 1996; 37:16S-19S. PubMed
  • Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med 1996; 37:19S-22S. PubMed
  • Kassis AI, Adelstein SJ. Preclinical animal studies with radioiododeoxyuridine. J Nucl Med 1996; 37:10S-12S. PubMed
  • Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med 1996; 37:315-20. PubMed
  • Kassis AI, Adelstein SJ. 5-[125]iodo-2'-deoxyuridine in the radiotherapy of solid CNS tumors in rats. Acta Oncol 1996; 35:935-9. PubMed
  • Mariani G, Di Sacco S, Bonini R, Di Luca L, Buralli S, Bonora D, Ricci S, Baranowska-Kortylewicz J, Adelstein SJ, Falcone A, Kassis AI. Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncol 1996; 35:941-5. PubMed
  • Adelstein SJ. Merrill C. Sosman Lecture. The Auger process: a therapeutic promise? AJR Am J Roentgenol 1993; 160:707-13. PubMed
  • Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991; 21:1541-51. PubMed
  • Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res 1990; 50:5199-203. PubMed
  • Makrigiorgos GM, Adelstein SJ, Kassis AI. Cellular radiation dosimetry and its implications for estimation of radiation risks. Illustrative results with technetium 99m-labeled microspheres and macroaggregates. JAMA 1990; 264:592-5. PubMed
  • Mariani G, Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI. Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications. Int J Rad Appl Instrum B 1988; 16:147-50. PubMed
  • Zalutsky MR, Venkatesan PP, English RJ, Shortkroff S, Sledge CB, Adelstein SJ. Radiation synovectomy with 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations. Int J Nucl Med Biol 1985; 12:457-65. PubMed
  • Bloomer WD, McLaughlin WH, Lambrecht RM, Atcher RW, Mirzadeh S, Madara JL, Milius RA, Zalutsky MR, Adelstein SJ, Wolf AP. 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. Int J Radiat Oncol Biol Phys 1984; 10:341-8. PubMed
  • Bloomer WD, McLaughlin WH, Adelstein SJ. Therapeutic implications of iodine-125 cytotoxicity. Int J Radiat Oncol Biol Phys 1982; 8:1903-8. PubMed
Hide